Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model
暂无分享,去创建一个
T. Niki | T. Masaki | Tomoko Tadokoro | A. Morishita | S. Fujihara | H. Iwama | Koji Fujita | T. Himoto | M. Hirashima | H. Mori | H. Kobara | N. Nishiyama | Taiga Chiyo | Nobuya Kobayashi | T. Yachida | Y. Goda | Takanori Matsui | Kyoko Ohura
[1] Wei-wei Wang,et al. miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1 , 2017, Japanese journal of clinical oncology.
[2] T. Niki,et al. Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. , 2017, Oncology reports.
[3] Li Wang,et al. A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. , 2017, International journal of surgery.
[4] Ken Kato,et al. Chemoradiotherapy for esophageal squamous cell cancer. , 2016, Japanese journal of clinical oncology.
[5] S. Dhar,et al. Nanotechnology inspired tools for mitochondrial dysfunction related diseases. , 2016, Advanced drug delivery reviews.
[6] T. Niki,et al. Galectin-9: An anticancer molecule for gallbladder carcinoma. , 2016, International journal of oncology.
[7] Ahmedin Jemal,et al. Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[8] T. Niki,et al. Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. , 2015, Oncology reports.
[9] P. Stephens,et al. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. , 2015, The oncologist.
[10] X Zhang,et al. Upregulation of miR-582-5p inhibits cell proliferation, cell cycle progression and invasion by targeting Rab27a in human colorectal carcinoma , 2015, Cancer Gene Therapy.
[11] M. Napimoga,et al. Galectin-9 as an important marker in the differential diagnosis between oral squamous cell carcinoma, oral leukoplakia and oral lichen planus. , 2015, Immunobiology.
[12] T. Niki,et al. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. , 2015, International journal of oncology.
[13] Q. Ye,et al. miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3 , 2015, Tumor Biology.
[14] A. Griffioen,et al. Galectin expression in cancer diagnosis and prognosis: A systematic review. , 2015, Biochimica et biophysica acta.
[15] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[16] T. Masaki,et al. miRNA in hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[17] Yin-Ji Li,et al. Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction , 2014, Laboratory Investigation.
[18] Siew Wui Chan,et al. Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[19] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[20] T. Niki,et al. Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies , 2014, The Journal of experimental medicine.
[21] C. Decaestecker,et al. Galectin fingerprinting in naso-sinusal diseases , 2014, Oncology reports.
[22] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[23] N. Kosaka,et al. Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] T. Niki,et al. The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells , 2012, The Journal of investigative dermatology.
[25] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[26] M. Taniwaki,et al. Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia , 2010, Molecular Cancer Research.
[27] Jessica A. Randall,et al. Correction: A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PLoS ONE.
[28] M. Taniwaki,et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways , 2010, Leukemia.
[29] Jessica A. Randall,et al. A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PloS one.
[30] T. Niki,et al. Galectin-9 Is a High Affinity IgE-binding Lectin with Anti-allergic Effect by Blocking IgE-Antigen Complex Formation , 2009, The Journal of Biological Chemistry.
[31] T. Niki,et al. Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions1 , 2008, The Journal of Immunology.
[32] D. Dhanasekaran,et al. JNK signaling in apoptosis , 2008, Oncogene.
[33] B. Levine,et al. Dual Role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation , 2008, Autophagy.
[34] W. Chow,et al. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.
[35] T. Niki,et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.
[36] A. Yamauchi,et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.
[37] J. Hirabayashi,et al. Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family. , 2007, Glycobiology.
[38] Azad Bonni,et al. p38 MAP Kinase Mediates Apoptosis through Phosphorylation of BimEL at Ser-65* , 2006, Journal of Biological Chemistry.
[39] Farin Kamangar,et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] V. Kuchroo,et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.
[41] Phillip D. Zamore,et al. Ribo-gnome: The Big World of Small RNAs , 2005, Science.
[42] M. Hirashima,et al. Development of highly stable galectins: Truncation of the linker peptide confers protease‐resistance on tandem‐repeat type galectins , 2005, FEBS letters.
[43] M. J. Abedin,et al. Galectin-9 Induces Apoptosis Through the Calcium-Calpain-Caspase-1 Pathway1 , 2003, The Journal of Immunology.
[44] Robert L Moritz,et al. Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.
[45] Xiaodong Wang,et al. Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.
[46] M. Hirashima,et al. Human Ecalectin, a Variant of Human Galectin-9, Is a Novel Eosinophil Chemoattractant Produced by T Lymphocytes* , 1998, The Journal of Biological Chemistry.
[47] H. Handoko,et al. The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells , 2012 .
[48] 永原 慶子. Galectin-9 increases Tim-3[+] dendritic cells and CD8[+] T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions , 2009 .
[49] A. Yamauchi,et al. Galectin-9 in physiological and pathological conditions , 2004, Glycoconjugate Journal.
[50] S. Srinivasula,et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity , 2002, Cell Death and Differentiation.